Vaxcyte Announces VAX-31 Vaccine Meets All Primary Endpoints in Phase 3 Study

Key Facts

Vaxcyte announced that its VAX-31 vaccine met all prespecified primary endpoints in the pivotal Phase 3 OPUS-1 study. According to a company statement released via GlobeNewswire, the trial successfully demonstrated the vaccine's safety and immunogenicity profile in adult participants.

The study compared VAX-31 against existing competitors Prevnar 20 and Capvaxive to evaluate its potential in providing broader protection against pneumococcal disease. Shares of PCVX closed at $56.48 on October 2, 2026, with a session high of $57 and a low of $55.84.